KEAP1 and cancer: Additionally, unregulated activation of Nrf2 can have detrimental consequences, with prolonged, ubiquitous activation shortening lifespan in Drosophila[23], and mutations in the Nrf2 inhibitor Keap1 (kelch-like ECH-associating protein 1) causing cancer in humans[24].